Can home spirometry and FeNO testing improve asthma diagnosis?

– a feasibility study

Ran Wang[1, 2] PhD, Alexander Thompson[3], Miriam Bennett[1, 2], MBChB, PhD, Angela Simpson[1,2]MD, PhD, Stephen J Fowler[1,2]MD, Hannah J Durrington[1, 2]PhD and Clare S Murray[1,2]MD

1. Division of Immunology, Immunity to Infection & Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, United Kingdom.

2. NIHR-Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, United Kingdom

3. Manchester Centre for Health Economics, University of Manchester, United Kingdom.

Corresponding author:

Dr Ran Wang

2nd floor Education Research Centre

Wythenshawe Hospital

Southmoor Road

Manchester

M23 9LT

Email: ran.wang-2@manchester.ac.uk

Manuscript type: Original Research

Word count: 3674; Reference: 46; Table: 2, Figures 3; Abstract: 300

Contributorship Statement: RW contributed to the conception of the study, funding acquisition, study set-up and planning, data collection, data analysis, and drafting of the submitted manuscript. AT contributed to the conceptualisation of the health-economic feasibility study design, health-economic data analysis, writing and review of the manuscript. MB, AS, and SJF contributed to data acquisition and manuscript writing. HJD contributed to critical review of the study design, review of data and manuscript. CSM

contributed to study conception, planning and set-up, study oversight, data acquisition, and writing and reviewing of the submitted manuscript. SJF, AS and CSM formed the Expert panel.

Acknowledgement: We would like to thank the RADicA study participants for their time and commitment to the study and the RADicA study team for help with data collection.

RW, MB, AS, SJF, HD and CSM are supported by the NIHR Manchester BRC. RW is supported by NIHR Clinical Lectureship (CL-2023-06-003). HJD is supported by MRC-CSF-MR/V029460/1

Competing Interests statement: We declare no competing interests.

%Data sharing statement: The authors will consider all reasonable requests for deidentified data, following approval by the study sponsors. Proposals should be directed to research.sponsor@mft.nhs.uk. To gain access, data requestors will need to sign a data access agreement.

Funding: This study was funded by National Institute for Health Research (NIHR) Research for Patient Benefit Grant (NIHR203591) and supported by the Manchester NIHR Biomedical Research Centre (BRC) (grant no. BRC-1215-20007, and NIHR203308), Asthma UK/Innovate (grant no. AUK-PG-2018-406) and North West Lung Centre Charity. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care

ABSTRACT:

Introduction: Although temporal variation is the hallmark of asthma, recommended diagnostic approaches largely rely on single clinic-based measurements. Ambulatory monitoring captures diurnal and day-to-day variability and may therefore enhance diagnostic accuracy. We evaluated the clinical feasibility and potential utility of home spirometry and fractional exhaled nitric oxide (FeNO) monitoring in asthma diagnosis.

Methods: Symptomatic, untreated adults with GP-suspected asthma underwent diagnostic tests including bronchodilator reversibility, in-clinic FeNO, blood eosinophil counts and bronchial challenge. Participants measured spirometry and FeNO four times daily over one week; during the second week spirometry were measured twice daily. The reference standard was provided (asthma/not-asthma) by an expert panel of at least two asthma specialists based on clinical history and the results of all in-clinic testing; home spirometry (except for peak expiratory flow) and FeNO measurements were blinded to the panel.

Results: Of 67 eligible participants, 51(76%) were recruited, and 38 had asthma confirmed or excluded by the panel. 1058 home spirometry measurements were obtained from 37(73%) participants; 848 home FeNO readings were obtained from 39(76%) participants. Among those completing at least one home measurement, median (IQR) adherence was 66.7(58.6-97.6)% for spirometry and 78.5(51.8-103.6)% for FeNO. Collection of health impact data for economic evaluation was feasible. In participants with a confirmed diagnostic outcome who completed home measurements (FeNO: n=32; spirometry: n=28), the putative home-testing metrics demonstrated high sensitivities at ≥90% specificity, and outperformed peak expiratory flow diurnal variability. Incorporating home testing into the BTS/NICE/SIGN 2024 diagnostic pathway had the potential to reduce reliance on bronchial challenge testing by 65%.

Conclusions: Home spirometry and FeNO testing and the prospective collection of health-economic data in the diagnostic setting were feasible. Home-based testing strategy showed early potential to improve asthma diagnosis and pathway efficiency. These findings support further evaluation through an adequately powered diagnostic accuracy study and health-economic assessment.

Key messages

- **What is already known on this topic:** Asthma can be difficult to diagnose, as objective tests may be normal when assessments are performed during periods of minimal or intermittent symptoms.

- **What this study adds:** Our data suggest that home spirometry and FeNO monitoring could be successfully implemented within a diagnostic accuracy trial. Participants were able to perform these tests reliably in the home environment.

- **How this study might affect research, practice or policy:** The early findings suggest that home-based physiological monitoring may offer additive diagnostic value beyond standard clinic-based assessments and could reduce reliance on bronchial challenge testing. These results provide a clear rationale for larger diagnostic accuracy trials and for undertaking early health-economic modelling to assess the potential impact on clinical pathways and resource utilisation.

INTRODUCTION

Asthma is the most common chronic airways disease in the UK[1], with approximately 160,000 new diagnoses made per year [1-3]. Yet, overdiagnosis affects up to 1 in 3 people who are receiving treatment for asthma[4,5] and underdiagnosis is as common (19-73%)[6]. Diagnostic delays and misdiagnosis lead to substantial avoidable harm for patients and place a significant burden on healthcare systems[4,7,8]. In contrast, early and accurate diagnosis, followed by appropriate treatment, can reduce unscheduled healthcare utilisation and improve asthma outcomes[9].

The definition of asthma highlights its intrinsic nature of temporal variability. However, the current clinic-based diagnostic approach relies on one-off time-point assessments, regardless of whether individuals are experiencing their usual symptoms at the time[10]. Mounting evidence suggests that asthma exhibits marked temporal variations in disease pathophysiology [11,12 13-17], with timing of test measurements influencing diagnostic outcome and clinical decision-making. [11,13,16,18]. While the Global Initiative for Asthma (GINA) 2025 strategic report recognises the impact of timing of diagnostic measurements and recommends performing key objective testing when patients are symptomatic or in the morning[19], achieving this in routine care requires flexible and rapid access that is rarely available in practice. Peak expiratory flow diurnal monitoring is currently the only home-based test for asthma; however, its poor diagnostic yield limits clinical utility, and is only recommended when spirometry is not available[10].

Advances in technology now allow tests previously restricted to clinical settings to be performed at home using portable devices, allowing flexible timing of measurements and better capture of variability in airflow limitation and airway inflammation[17]. Whilst early stakeholder evaluations suggest that undertaking home spirometry and fractional exhaled nitric oxide (FeNO) testing at the diagnostic setting are acceptable and welcomed by both patients and healthcare professionals when adequate support is provided [20,21], their clinical feasibility and potential to improve diagnostic accuracy remains uncertain.

This study aimed to evaluate the feasibility and potential diagnostic utility of home-based spirometry and FeNO testing for asthma diagnosis.

METHOD

Study procedures

Routine tests:

The study is nested in the Rapid Asthma Diagnostics for Asthma study (RADicA, https://www.radica.org.uk, ISRCTN 11676160)[20]. Briefly, symptomatic and untreated adults (defined as $\geq$16 years with no inhaled or systemic corticosteroid use for at least 4 weeks) with GP-suspected asthma were recruited from primary care. Clinical history was taken and physical examination carried out. All participants had FeNO (NIOX VERO, Circassia, UK, and NOBreath, Bedfont, UK) measured in clinic, spirometry and bronchodilator reversibility (BDR) and bronchial challenge testing (BCT, mannitol and/or methacholine) performed [22]. Participants were asked to refrain for caffeine containing beverages and food 6 hours prior to in-clinic FeNO and short-acting bronchodilator for 8 hours prior to BDR. All participants were skin prick tested for eight common inhaled allergens, blood eosinophil counts measured, and 5-item asthma control questionnaire (ACQ-5) assessed[22,23]. A trial of inhaled steroids (ICS, fluticasone propionate 250mcg twice daily) was given for 4-8 weeks before diagnostic tests repeated (Figure 1).

Home testing

Prior to initiation of ICS, all participants were provided with home spirometry (MIR Spirobank Smart, Intermedical, UK) and FeNO (NOBreath, Bedfont, UK) devices. With permission, the mobile software application ('app', MIR Spiro Software) associated with the spirometers was downloaded, set up and installed on the participants' smartphones in the RADicA clinic during their appointments. The MIR Spiro software is compliant with the international ATS/ERS guidelines[24] and standards for spirometry. The app software also provides a virtual assistant for users to achieve optimum spirometry blow technique. In-person training and written instructions were provided for both devices; the time taken for training for each test were recorded.

Participants were asked to perform FeNO and spirometry tests 4 times a day at home, e.g. 4-5 hourly ($\pm$1hr) when awake (e.g. 0600-0800, 1100-1300, 1600-1800, 2100-2400hr) and whenever symptomatic for one week. During the second week, participants were asked to

use the spirometer twice-daily (0600-0800 and 2100-2400hr), and to use both spirometry and FeNO whenever they have symptoms. As diurnal PEF monitoring over two weeks remains a recognised diagnostic parameter[2,10], this schedule is designed to mirror established PEF protocol and to evaluate whether home spirometry and FeNO could feasibly capture similar longitudinal variability within a similar timeframe and test frequency. The four-times-daily schedule in the first week was to enable characterisation of diurnal patterns in test parameters and identification of optimal time points for future refinement.

Participants were told to measure FeNO prior to spirometry measurements, and prior to reliever use whenever possible (and repeat 15-20 minutes after if the reliever was taken). There were no dietary or specific lifestyle changes advised. Visual Analogue Scale (VAS) were used to self-rate symptom burden at time of testing using diary book (Figure E1). All participants were asked to complete a test acceptability questionnaire following the testing period. A subgroup of participants were also invited to take part in a qualitative interview (results published elsewhere)[21].

Health-economic parameters were collected at Visit 2 using participants administered questionnaire; EQ-5D-5L is assessed daily during home testing period with questionnaire embedded within the diary booklet.

Symptoms, EQ-5D-5L, and home FeNO measurements were recorded in a diary booklet, while home spirometry reports were collected via the app and emailed by participants after each test.

Reference standard

The reference standard was established by an expert panel comprising at least two asthma specialists (from SJF, CSM and AS), who confirmed or refuted an asthma diagnosis using all available clinical and routine test data (Figure 1)[22]. Home-based spirometry (except for PEF diurnal variability) and FeNO results were blinded to panel members and were not used to inform the diagnostic recommendation.

The study protocol was approved by the North West-Greater Manchester East Research Ethics Committee (18/NW/0777); all participants gave written informed consent.

<u>Outcomes</u>

The primary outcomes were recruitment and retention rates and test adherence; key secondary outcomes included equipment loss/damaged/failure rate, proportion of patients diagnosed with asthma by the joint British Thoracic Society, National Institute for Health and Care Excellence and the Scottish Intercollegiate Guidelines Network 2024 (BTS/NICE/SIGN 2024) pathway[10] and by expert panel, putative metrics in asthma and non-asthma and their discriminative ability against enhanced reference standard and the feasibility of collecting data for health-economics evaluation.

<u>Sample size</u>

A sample size of 50 participants was considered sufficient for a feasibility study, enabling estimation of primary feasibility outcomes while providing preliminary diagnostic performance estimates to inform future definitive studies[25].

<u>Statistical analysis</u>

Feasibility data were summarised using descriptive statistics. Adherence rate was estimated based on the proportion of expected measurements successfully received. All FeNO measurements were considered valid and included in subsequent exploratory analyses. For home spirometry, only measurements meeting a minimum quality threshold of grade C or higher were included[26], unless otherwise stated.

For home-based longitudinal data, multilevel intraclass correlation coefficients (ICC) were used to quantify variance attributable to between-participant, day-to-day, and within-day differences, estimated using mixed-effects models (lme4 and performance R packages). Repeated-measures correlation was used to quantify within-participant associations between objective measures and symptom scores, accounting for repeated observations (rmcorr R package) and were further examined using linear mixed-effects regression models (lme4 packages). Non-parametric data were log-transformed prior to analysis. Diurnal variability of peak expiratory flow (PEF) over 2 weeks were measured using home spirometry and calculated using formula: $\sum[(Maximum-minimum)/mean]/(number\ of\ days) \times 100$.

Putative home diagnostic metrics: Given that asthma is characterised by variable airflow limitation[19], putative spirometric indices reflecting within-individual variability in airflow obstruction (e.g. in % predicted forced expiratory flow within in 1 second [FEV_1 % predicted] and PEF) were evaluated. For home FeNO testing, both average and variability-based parameters were examined, given their reported associations with relevant clinical outcomes[17,27].

Diagnostic performances of the putative home testing parameters were assessed using receiver operating characteristic area under the curve (AUROC) analysis (pROC package). As no single asthma diagnostic tests is sufficient to rule out asthma, the national and international diagnostic guidelines adopt sequential rule-in approaches [10,19,28] and high specificity tests (low false positive rate) are prioritied[10]. We report putative diagnostic thresholds and the corresponding sensitivity estimates achieving ≥90% specificity. Confidence intervals for AUC, sensitivity, and specificity were derived using bootstrap resampling with n=1000 iterations.

All analyses were conducted using R (version 4.5.1) within RStudio (Version 2023.12.1).

Patient and public involvement

A Patient Advisory Group (PAG) comprising five members with asthma or caring for someone with asthma. Members of PAG contributed to designing and reviewing of all patient-facing materials, including diary book (Figure E1), device training materials and instructions, participant information sheets and consent forms. One PAG member also served on the trial steering committee.

RESULTS:

Feasibility

<u>Study feasibility and test adherence</u>

Of 67 eligible participants, 51 (76%) consented to participate in the sub-study. Two-thirds (63%) were recruited from areas in the most deprived tertile of the Index of Multiple Deprivation. There was no difference in baseline characteristics between those who

consented and declined (Table 1). Of the 51, definitive diagnosis could be confirmed by the expert panel in 38 participants (25 [65.8%] of whom had asthma) (Table E1). Following the current NICE 2024 guidance[10], 43 participants had confirmed diagnostic outcome, of whom 67.4% had asthma (Table E2). Agreement between BTS/NICE/SIGN 2024 and expert panel enhanced reference standard was 78.4%.

Whilst 1058 home spirometry measurements were obtained from 37 (72.5%) participants, of which 602 (56.9 %) were of adequate quality (grade C or above), 848 home FeNO readings were obtained from 39 (76%) participants (Figure E2-3). Of those who performed at least one home measurement, the median (IQR) adherence rate for spirometry was 66.7 (58.6-97.6) % and FeNO 78.5 (51.8-103.6) %.

There were no devices lost or damaged. One participant experienced difficulty using the spirometry app during an app update period. In three participants, non-attendance at the follow up visit 2 necessitated retrieval of the device by travelling to the participant's home. The median (IQR) training time was 9.0 (6.8–11.0) minutes for home spirometry and 5.0 (2.5–7.0) minutes for FeNO. Home testing strategy using both tests were acceptable in most participants (Figure E4-5).

Feasibility of health economics data collection

Daily EQ-5D-5L: During the home testing period, 35 participants (68.6%) completed at least one daily EQ-5D-5L assessment, providing 307 participant-days of utility data. Completion rates were similar between participants with and without asthma.

Daily EQ-5D-5L diary completion during home testing period declined from 62.7% (32/51) on day 1 to 19.6% (10/51) on day 14, with a mean daily completion rate of 43.0% across the 14-day monitoring period (Figure E6A). Participants from the most deprived areas (IMD deciles <3) reported lower mean utility than those from less deprived areas throughout the monitoring period (Figure E6B), though wide confidence intervals reflect small subgroup sizes. Participant engagement was bimodal: approximately one-third completed no diary days, while those who engaged typically completed 11 or more of the 14 days. When the

diary was attempted, all five dimensions were consistently completed with no selective item non-response.

Median (IQR) EQ-5D-5L utility index (England value set)[29] was 0.940 (0.831-1.000), with 43.6% of observations at full health. Pain/discomfort was the most frequently reported problem (48% reporting any level of problems), followed by anxiety/depression (38%) and usual activities (36%). Most participants reported no problems with self-care (88%) or mobility (82%) (Table E3, Figure E7).

Health impact questionnaires: Health impact questionnaires were completed by 37 participants (72.5%; 33 with a diagnostic outcome); completion rates for health impact measures, productivity data and out-of-pocket costs all exceeded 70%. 30% (11/37) of participants reported at least one unscheduled healthcare utilization due to respiratory symptoms within the previous 3 months, comprising unscheduled GP contacts (n=9), NHS 111 calls (n=3), and emergency department attendances (n=2). Overall, 71% of participants provided data sufficient for economic costing across all three domains (healthcare contacts, out-of-pocket costs, and productivity impact) (Figure E8).

Exploratory analyses

Longitudinal variability

The variability observed in subjective symptoms, and objective home FeNO and spirometry measurements was substantial (Figure 2, Figures E9-E16). 18 (46.2%) participants had home FeNO readings that straddled the diagnostic cut-off of 50ppb, and 8 (29.6%) with grade C or above spirometry readings straddled 70% for FEV_1/FVC ratio. In those with asthma, the inter-individual variation in log (FeNO) accounted for 85.6 [77.7-91.1]% of total variance observed, 7.4 [4.5-12.5] % variance was observed within day and 6.6 [3.1-12.6] % between-day; this is similar for FEV_1 % predicted (inter-individual: 78.5 [55.9-88.1]%, between-day: 10.9 [4.3, 23.0]% and within-day 10.7 [3.8-27.4]%) (Figures E6-10). Whilst FEV_1 % predicted and FEV_1/FVC measured between 2PM and 8PM were higher than at other time points, FeNO was higher between 8 AM and 2 PM (Figures E17-E22).

Increased symptoms weakly correlated with reduced FEV_1 % predicted (r=-0.22 [95%CI: -0.32, 0.11], p<0.001), FVC % predicted (-0.121 [-0.228, -0.012], p=0.030) and FEV_1/FVC (-0.17 [-0.27, -0.01], p=0.003), but not with FeNO (p=0.552). FeNO was correlated with FEV_1 % predicted (0.14 [0.04, 0.23], p=0.009) and FVC % predicted (0.114 [0.013, 0.213], p=0.027). Low symptom scores at time of testing (VAS <4) were associated with higher FEV_1% predicted (β = 5.39, 95% CI [3.20, 7.57]; p < 0.001) and FVC% predicted (5.06 [2.91, 7.17], p< 0.001) compared to tests done during high symptom period (VAS ≥4).

Putative diagnostic parameters

Twenty-eight participants with a confirmed diagnostic outcome completed more than one home spirometry measurement, and 32 participants with a confirmed diagnostic outcome completed home FeNO testing; these participants were included in the analysis to estimate the potential diagnostic utility of the putative home-testing parameters.

The maximum fluctuation in observed home FEV_1% predicted ($FEV_1\%Pred_{max-min}$) was higher in those with asthma versus those without (p=0.016). The variations in FEV_1 % predicted was evaluated as it adjusts for individuals' demographics and is a recommended parameter for assessing bronchodilator reversibility by the European Respiratory Society and American Thoracic Society technical standard (2022)[24]. In contrast, variability metrics based on day-to-day PEF fluctuation showed poorer diagnostic performance (Table 2, Figure E23). Using higher quality spirometry measurements (grade B above, or Grade A only) did not show better discriminative abilities (Table E4).

All home FeNO-derived parameters were higher in individuals with asthma compared with those without (p<0.05, Figure E24) and had high AUC and sensitivity whilst maintaining specificity of >90% (Table 2, Figures E25).

Comparison with routine tests

A median (IQR) of 9.0 (6.0-11.8) days of diurnal home PEF (PEFv) data were obtained from 34 (66.7%) participants, irrespective of spirometry quality Grade. Of the 34 participants, 28 had confirmed diagnostic outcomes. Only four of these completed ≥14 days of twice-daily peak flow readings; all four had asthma, but none demonstrated ≥20% mean diurnal PEF variability. All clinic-based routine tests demonstrated high specificity (≥90%) using established cut off values (Table 2).

Clinic-based FeNO showed strong correlation with home $FeNO_{median}$ (r=0.95 [0.90–0.98], p < 0.001) but only moderate agreement with 95% limits of agreement of -29.7 to +42.2 ppb (Figures E26). Lowering the diagnostic cut-off for clinic-based FeNO improved sensitivity but reduced specificity (69.2-84.6%, Table E4), depending on the threshold applied.

Integration into diagnostic pathway

Mapping the home-based diagnostic strategy onto the current BTS/NICE/SIGN 2024 adult pathway[10] reduced the need for BCT by 65% (Figure 3), equivalent to offering home testing to 1.5 (95% CI [1.3–2.2]) patients to avoid one bronchial challenge test. Among 37 participants who had a confirmed diagnostic outcome who completed all BTS/NICE/SIGN 2024 pathway tests, the integrated home testing pathway achieved 94.6% accuracy (35/37) compared with 89.2% (33/37) for the current BTS/NICE/SIGN 2024 pathway, whilst leading to a reduction of 78.3% (18/23) who would have required BCT (Figure E27).

DISCUSSION

Home-based spirometry and FeNO testing and the prospective collection of health-economic data required for formal economic evaluation are feasible. The putative metrics in home testing generated better diagnostic yield than currently available home PEFv; integration of these tests into the current BTS/NICE/SIGN 2024 pathway has the potential to reduce the need for BCT[10].

Longitudinal monitoring is routine in other conditions, such as hypertension, where ambulatory blood pressure monitoring reduces overdiagnosis arising from single clinic measurements and is now embedded in primary care.[30,31] Asthma biomarkers, including

airflow obstruction and airway inflammation, are also dynamic[11,13,14,17]. Indeed, consistent with our previous work, we demonstrated marked temporal variability in diagnostic biomarkers[17]; this is without change in treatment. Home FEV_1 variability may reflect bronchial hyperresponsiveness to everyday stimuli (e.g., exercise or environmental triggers) or effect of BDR when reliever bronchodilators are used when symptomatic, as well as circadian influence[11,13,14,32], but can also arise from fluctuating variable airway inflammation. It is also important to note that we confirmed diurnal variability in FeNO under real-world conditions with substantially less stringent environmental, dietary and medication control than in controlled circadian studies[14-16]. These findings underscore the importance of longitudinal measurements for asthma diagnosis.

To date, diurnal PEF variability remains the only widely available, low-cost home-based diagnostic tool for asthma diagnosis[10]. However, PEFv measurements and interpretations remains problematic: adherence to twice-daily measurements, suboptimal test technique and challenges with accurate documentation of results limits its clinical utility [33-35]. We have previously observed low diagnostic yield for PEFv in an independent cohort, with only 14% of participants completing the recommended 14 days of monitoring, even within research settings[10,28,35]. Furthermore, even when completed, PEFv demonstrates poor diagnostic sensitivity (~15%)[36,37], reflecting its limited ability to detect airflow obstruction. As a result, NICE recommends PEFv testing only when spirometry is not available[10]. Digital approaches using more sensitive biomarkers, such as FEV_1, may therefore improve both test adherence and diagnostic yield[38].

The utility of FeNO and its diagnostic threshold for asthma diagnosis remains debated across major guidelines [10,28,39]. While NICE 2024 and ERS 2022 recommend FeNO as a rule in test and recommended a threshold of ≥50 ppb in adults, the National Asthma Education and Prevention Program (NAEPP) 2020 focused update uniquely suggests FeNO< 20ppb in steroid naïve individuals makes asthma diagnosis unlikely, with intermediate values (25-50ppb) considered indeterminate [39]. The wide overlap in FeNO values between individuals with and without asthma is likely contributed by unaccounted temporal variability[40]. Therefore, repeated FeNO measurements during the diagnostic process, particularly in steroid-naïve individuals, may better reflect an individual's overall inflammatory burden and

improve diagnostic certainty with a lower diagnostic cutoff value. Future studies should investigate whether home FeNO testing can enhance diagnostic accuracy in patients with indeterminate clinic-based FeNO results. Furthermore, we demonstrated substantial intra-individual variability in FeNO even in the absence of treatment change, indicating that single measurements are insufficient to reliably quantify inflammatory burden and that repeated measurements may be necessary before establishing a minimally clinically important difference for FeNO-based treatment response in patients[41]. Notably, we found that within-individual increases in FeNO were associated with increased airway calibre at time of testing, consistent with prior reports.[42] This highlights potential opportunities to digitally integrate home FeNO and spirometry parameters within algorithm-based approaches, with advanced metrics optimised using machine-learning methods to further enhance diagnostic performance.

It is important to note that the data from the RADicA study contributed to the development of the BTS/NICE/SIGN 2024 pathway[43]. The current study used a similar study design, enabling a robust evaluation of pathway fit of the home-based testing strategy. The current data were prospectively collected following data sharing with NICE and are independent of the dataset that informed the guidance. The NICE estimated that approximately 63% of patients require BCT following their pathway[43]; consistent with this, 69% of those with suspected asthma progressed to BCT in the current cohort, highlighting a major implementation bottleneck given its restriction to secondary care. Development of novel diagnostic technologies and strategies that safely reduce reliance on BCT would therefore be of clear value. However, making such home-based testing approaches viable at scale require knowledge of the barriers and facilitators of test uptake from key stakeholders[20,21,44], health-economic evaluation as well as clinical validation. Crucially, our findings show that diagnostic performance in unselected populations does not translate directly within sequential pathways, where pre-test probability changes depending on order of tests. Evaluation of novel diagnostics must therefore move beyond standalone accuracy but to assess performance at the pathway level.

Limitations

This study is limited by its small sample size, reflecting its feasibility design and resulting in wide confidence intervals. Nevertheless, feasibility was evaluated in a setting representative of real-world diagnostic practice, including a demographically diverse population, with most participants recruited from highly deprived areas. However, digitally-excluded individuals and shift workers may be less-represented, potentially limiting generalisability to these groups; this is particularly relevant given evidence that shift workers are at increased risk of asthma[45]. Barriers and facilitators to digital home-testing strategies therefore warrant further investigation in these populations.

Peak expiratory flow was derived from spirometry manoeuvres rather than standalone peak flow testing, and digital recording may have improved adherence rate compared with conventional paper-based PEF diaries; adherence observed here may therefore overestimate real-world PEF diurnal variability completion. Furthermore, in-clinic FeNO measurements were performed following avoidance of caffeine, whereas this was not required during home testing for practical and adherence considerations, which may have contributed to the variability observed. However, it is important to highlight that evidence regarding the effect of caffeine ingestion on FeNO remains controversial[46]. FeNO is commonly used as a point-of-care test in routine clinical practice, where dietary factors are not strictly controlled; therefore, the observed variability remains clinically relevant.

In addition, neither the FeNO device nor the home spirometer was designed specifically for diagnostic use in the home. Accordingly, this was not a device validation study but an evaluation of participant ability to perform home testing and the potential clinical utility of these measurements. Nevertheless, our findings highlight new opportunities for device optimisation for diagnostic use. It is also important to note that the four-times-daily testing schedule was used for feasibility evaluation and is unlikely to be the strategy in future studies; our findings suggest that targeting specific time-of-day windows and symptom periods could substantially reduce testing burden while maintaining diagnostic accuracy.

CONCLUSION

Home-based spirometry and FeNO testing were feasible and showed early potential to improve asthma diagnosis and pathway efficiency. Future work should prioritise early

health-economic evaluation and adequately powered diagnostic accuracy studies with optimised study design to validate these approaches. Uptake and adherence in routine care may be further improved through better device design, clearer outputs, and appropriate education and technical support. Importantly, this study provides a generalisable framework for evaluating novel diagnostic technologies within diagnostic pathways.

TABLES AND FIGURES:

Table 1. Baseline characteristics table in those who consented and declined participation in home testing.

	Declined (n=16)	Consented (n=51)	p-value
Male, n (%)	6 (37.5%)	21 (41.2%)	1
Age, yrs, median (IQR)	32.5 (22.8- 39.5)	30 (21.0, 39.0)	0.837
Ethnicity, white, n (%)	7 (43.8%)	28 (56.0%)	0.832
Index of Multiple Deprivation (decile<3), n (%)	9 (56.3%)	32 (62.7%)	0.864
Body mass index, kg/m^2	28.0 (24.3-32.2)	28.1 (24.1-35.2)	0.686
Shift worker, n (%)	6 (37.5%)	7 (14.0%)	0.083
ACQ points at presentation	1.6 (0.8-2.4)	1.4 (0.6-2.2)	0.636
Lost in follow up*	2 (12.5%)	8 (15.6%)	1
% asthma diagnosis	10 (62.5%)	25 (49.0%)	0.665

Did not attend at visit 2

Table 2. Diagnostic efficiencies of routine tests and home-based testing metrics in participants who had confirmed diagnostic outcome (asthma and not asthma, n=38).

Potential parameters[§]	Number (n)	AUC_{ROC}	Threshold for specificity to be >90% for home tests; or established threshold for routine tests	Sensitivity	Specificity
Home-based testing					
Home spirometry parameters					
$FEV_1\%Pred_{max-min}$, (%)	28	0.78 (0.62-0.95)	≥16%	52.4 (28.6-71.4)%	100 (100-100)%
$PEF_{max-min\%}$, (%)	28	0.61(0.38-0.84)	≥50%	19.1 (4.7-38.1)%	100 (100-100)%
Home FeNO parameters					
$FeNO_{median}$ (ppb)	32	0.82 (0.65-0.99)	≥25	77.3 (59.1, 95.5)%	90.0 (70.0- 100.0)%
$FeNO_{median\_8AM-2PM}$ (ppb)	32	0.81 (0.63-0.99)	≥21	81.8 (63.6, 95.5)%	90.0 (70.0- 100.0)%
$FeNO_{maximum}$ (ppb)	32	0.80 (0.62, 0.97)	≥59	54.5 (31.8-72.7)%	90.0 (70.0- 100.0)%
$FeNO_{maximum\_8AM-2PM}$ (ppb)	32	0.82 (0.66 0.99)	≥43	72.7 (54.6-90.9)%	90.0 (70.0- 100.0)%
$FeNO_{IQR\_variability}$ (ppb)	32	0.76(0.58, 0.93)	≥12	50.0 (27.3-68.2)%	90.0 (70.0- 100.0)%
Routine tests					
Bronchodilator reversibility[∞] (% change in FEV_1)	38	0.92 (0.81-1)	≥12%	32.0 (16.0-52.0)%	100 (100-100)%
Bronchodilator reversibility[∞] (% change in FEV_1 % predicted)	38	0.93 (0.85-1)	≥10%	28.0 (12.0-44.0)	100 (100-100)%
Blood eosinophil count[∞] (x10^9 cells/L)	35	0.69 (0.49-0.88)	>0.4	45.8 (25.0-66.7)%	90.1 (72.7-100)%
FeNO (NIOX)[∞] (ppb)	38	0.80 (0.65-0.94)	≥50	44.0 (24.0-64.0)%	92.3 (76.9-100)%
FeNO (NOBreath) (ppb)[Ω]	32	0.77 (0.58-0.96)	≥50	31.8 (13.6-50.0)%	90.0 (70.0-100)%
Methacholine PD_{20}[∞] (mg)	31	1.00 (1.00 - 1.00)	<0.2	71.4 (52.4-90.5)%	100 (100-100)%

[§]**Equations**:

$FEV_1\%Pred_{max-min}$:maximum $FEV_1\%$ predicted − minimum $FEV_1\%$ predicted;

$PEF_{max-min\%}$: (maximum PEF − minimum PEF)/ minimum PEFx100;

$FeNO_{median}$: Median of all home FeNO measurements;

$FeNO_{median\_8AM-2PM}$: Median of all home FeNO measurements performed between 8AM and 2PM;

$FeNO_{maximum}$: Maximum of all home FeNO measurements;

$FeNO_{maximum\_8AM-2PM}$: Maximum of all home FeNO measurements performed between 8AM and 2PM;

$FeNO_{IQR\_variability}$: Interquartile range of all home FeNO measurements;

[β]Upper limit of normal for local laboratory reference range; [∞] Diagnostic outcomes were taken into account of NIOX FeNO measurements, BDR, BEC and BCT results; [Ω] In-clinic NOBreath measurements were blinded to the Expert Panel when confirming diagnostic outcomes.

PD20: provoking dose of methacholine in inducing 20% fall in FEV_1.

Figure 1. Study flow chart

Figure 2. Intra- and inter- individual variability of home FeNO and FEV_1 % predicted.

Figure 3. An example diagnostic strategy integrating home diagnostics into the BTS/NICE/SIGN 2024 adult asthma guideline pathway to reduce the need for bronchial challenge testing (BCT). This model begins with in-clinic FeNO and bronchodilator reversibility (BDR) testing (the first two steps of the BTS/NICE/SIGN 2024 pathway). For patients with negative in-clinic test results who would otherwise proceed to referral to secondary care for a BCT, home diagnostics are issued prior to discharge, guided by test results and technique quality. In patients with intermediate in-clinic FeNO (25-49ppb), additional longitudinal home FeNO monitoring may better capture overall airway inflammation than a single point measurement and therefore offers additional insight. In contrast, for those with low in-clinic FeNO (<25ppb), home spirometry may be a more appropriate option. Training for techniques in performing FeNO and spirometry could be delivered at the same time as patients are performing clinic-based tests, avoiding additional appointments or training time. Devices are returned after 1-2 weeks, with results reviewed and actioned remotely by healthcare professionals. This potential community-based one-stop-shop approach substantially reduces the number of patients who need referral to secondary care for BCT; in this cohort, 65% BCT could be avoided.

REFERENCES:

NHS England: RightCare asthma scenario: https://www.england.nhs.uk/long-read/rightcare-asthma-scenario/; (2023); accessed 15/04/2026

British Thoracic Society: Asthma, https://www.brit-thoracic.org.uk/quality-improvement/clinical-resources/asthma/ (2025), accessed 15/04/2026

National Institute for Health and Care Excellence: Asthma prevalence. https://cks.nice.org.uk/topics/asthma/background-information/prevalence/; accessed 15/04/2026.

Aaron, S. D. *et al.* Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma. *Jama* **317**, 269-279 (2017).

Shaw, D. *et al.* A cross-sectional study of patterns of airway dysfunction, symptoms and morbidity in primary care asthma. *Prim Care Respir J* **21**, 283-287 (2012).

Kavanagh, J., Jackson, D. J. & Kent, B. D. Over- and under-diagnosis in asthma. *Breathe (Sheff)* **15**, e20-e27 (2019).

Pakhale, S., Sumner, A., Coyle, D., Vandemheen, K. & Aaron, S. (Correcting) misdiagnoses of asthma: a cost effectiveness analysis. *BMC Pulm Med* **11**, 27 (2011).

Orlovic, M. *et al.* Environmental, healthcare and societal impacts of asthma: a UK model-based assessment. *ERJ Open Research* **10**, 00577-02023 (2024).

Aaron, S. D. *et al.* Early Diagnosis and Treatment of COPD and Asthma - A Randomized, Controlled Trial. *N Engl J Med* **390**, 2061-2073 (2024).

BTS/NICE/SIGN Joint Guideline on Asthma: diagnosis, monitoring and chronic asthma management. https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/; (2024) accessed 15/04/2026.

Wang, R., Murray, C. S., Fowler, S. J., Simpson, A. & Durrington, H. J. Asthma diagnosis: into the fourth dimension. *Thorax* **76**, 624-631 (2021).

Wang, R. *et al.* Defining the normal range of fractional exhaled nitric oxide in children: one size does not fit all. *ERJ Open Research* **8**, 00319-02022 (2022).

Wang, R. *et al.* The impact of time of day on the diagnostic performance of tests for asthma. *ERJ Open Res* **10** (2024).

Wang, R. *et al.* The impact of dosage timing for inhaled corticosteroids in asthma: a randomised three-way crossover trial. *Thorax* **80**, 504 (2025).

Wilkinson, M. *et al.* Circadian rhythm of exhaled biomarkers in health and asthma. *European Respiratory Journal* **54**, 1901068 (2019).

Durrington, H. J. *et al.* Time of Day Affects Eosinophil Biomarkers in Asthma: Implications for Diagnosis and Treatment. *Am J Respir Crit Care Med* **198**, 1578-1581 (2018). https://doi.org/10.1164/rccm.201807-1289LE

Wang, R. *et al.* Domiciliary Fractional Exhaled Nitric Oxide and Spirometry in Monitoring Asthma Control and Exacerbations. *J Allergy Clin Immunol Pract* **11**, 1787-1795.e1785 (2023).

Hakizimana, A. *et al.* Effectiveness of paediatric asthma hubs: a clinical pilot study. *Arch Dis Child* **110**, 203-208 (2025).

Global Initiative for Asthma Strategic report 2025. https://ginasthma.org/2025-gina-strategy-report/ (2025); accessed 15/04/2026

Wang R, Lawton K, Khatoon B, Smith J, Fowler SJ, Simpson A, Murray CS. Expectations and attitudes in primary care towards home-based testing for diagnosing asthma: a mixed methods study. BJGP Open. 2026 Jan 5:BJGPO.2025.0260

Khatoon, B. *et al.* What do patients think about home-based testing for better asthma diagnosis? Insights from a qualitative study. *BMJ Open* **16**, e109347 (2026).

Murray, C. S. *et al.* Rapid Access Diagnostics for Asthma (RADicA): protocol for a prospective cohort study to determine the optimum series of investigations to diagnose asthma using conventional and novel tests. *BMJ Open* **14**, e083908 (2024).

Juniper, E. F., Svensson, K., Mörk, A. C. & Ståhl, E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. *Respir Med* **99**, 553-558 (2005).

Stanojevic, S. *et al.* ERS/ATS technical standard on interpretive strategies for routine lung function tests. *Eur Respir J* **60** (2022).

Sim, J. & Lewis, M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. *Journal of Clinical Epidemiology* **65**, 301-308 (2012).

Graham, B. L. *et al.* Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. *Am J Respir Crit Care Med* **200**, e70-e88 (2019).

Matsunaga, K., Hirano, T., Oka, A., Ito, K. & Edakuni, N. Persistently high exhaled nitric oxide and loss of lung function in controlled asthma. *Allergol Int* **65**, 266-271 (2016).

Louis, R. *et al.* European Respiratory Society guidelines for the diagnosis of asthma in adults. *Eur Respir J* **60** (2022).

Devlin, N. J., Shah, K. K., Feng, Y., Mulhern, B. & van Hout, B. Valuing health-related quality of life: An EQ-5D-5L value set for England. *Health Econ* **27**, 7-22 (2018).

Tucker, K. L. *et al.* Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. *PLoS Med* **14**, e1002389 (2017).

NICE guideline (NG136): Hypertension in adults: diagnosis and management 2019. https://www.nice.org.uk/guidance/ng136, accessed 15/04/2026

Scheer, F. *et al.* The endogenous circadian system worsens asthma at night independent of sleep and other daily behavioral or environmental cycles. *Proc Natl Acad Sci U S A* **118** (2021).

Garrett, J., Fenwick, J. M., Taylor, G., Mitchell, E. & Rea, H. Peak expiratory flow meters (PEFMs)--who uses them and how and does education affect the pattern of utilisation? *Aust N Z J Med* **24**, 521-529 (1994).

Côté, J., Cartier, A., Malo, J. L., Rouleau, M. & Boulet, L. P. Compliance with peak expiratory flow monitoring in home management of asthma. *Chest* **113**, 968-972 (1998).

Drake, S. *et al.* Diagnosing Asthma with and without Aerosol-Generating Procedures. *J Allergy Clin Immunol Pract* **9**, 4243-4251.e4247 (2021).

Simpson, A. J. *et al.* Asthma diagnosis: a comparison of established diagnostic guidelines in adults with respiratory symptoms. *EClinicalMedicine* **76**, 102813 (2024).

NICE 2024 evidence review C: diagnostic test accuracy of peak expiratory flow variabiity for diagnosis of asthma: https://www.nice.org.uk/guidance/ng245/evidence/evidence-review-c-accuracy-and-clinical-and-cost-effectiveness-of-peak-expiratory-flow-in-the-pdf-13558146736; accessed on 15/04/2026.

Antalffy, T., De Simoni, A. & Griffiths, C. J. Promising peak flow diary compliance with an electronic peak flow meter and linked smartphone app. *npj Primary Care Respiratory Medicine* **30**, 19 (2020). https://doi.org/10.1038/s41533-020-0178-y

National Asthma Education and Prevention Program 2020 focused updates to the Asthma Management Guidelines; https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates. Accessed 15/04/2026.

Dweik, R. A. *et al.* An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med* **184**, 602-615 (2011).

Noble, J. *et al.* External Validation of the Minimal Clinically Important Difference of FeNO Using the Asthma Control Questionnaire. *Clin Exp Allergy* **56**, 53-60 (2026).

Michils, A. *et al.* How Airway Caliber Affects FeNO Thresholds Used to Identify Type 2 Inflammation in Asthma. *J Allergy Clin Immunol Pract* **13**, 2397-2404 (2025).

BTS/NICE/SIGN collaborative guideline NG245, Economic analysis report. Asthma: diagnosis, monitoring and chronic asthma management (update): Cost-utility analysis: Most cost-effective sequence or combination of tests to diagnose asthma. November 2024, accessed on 03/04/2026

Khatoon, B. *et al.* What do patients think about home-based testing for better asthma diagnosis? - Insights from a qualitative study. *medRxiv*, 2025.2008.2013.25333591 (2025).

Maidstone, R. J. *et al.* Night shift work is associated with an increased risk of asthma. *Thorax* **76**, 53-60 (2021).

Taylor, E. S., Smith, A. D., Cowan, J. O., Herbison, G. P. & Taylor, D. R. Effect of caffeine ingestion on exhaled nitric oxide measurements in patients with asthma. *Am J Respir Crit Care Med* **169**, 1019-1021 (2004).

Home diagnostics strategy

Is in-clinic FeNO between 25 and 49ppb?

Yes

Home FeNO

n=10

n=2, negative

n=7 positive
True asthma: n=7

Treat for asthma

n=1 did not perform home FeNO

No, <25ppb

Home Spirometry

n=26

n=4 positive,
asthma; n=3
uncertain; n=1

Treat for asthma

N=10 negative

Not asthma: n=8
Asthma: n=1;
Uncertain: n=1

Consider alternative diagnosis

BTS/NICE/SIGN 2024 pathway
Community-based

n=51 suspected asthma

one-off in-clinic FeNO (≥50ppb)

N=13; positive, treat asthma
True asthma, n=11
not asthma, n=1
uncertain, n=1

n=1 unable to perform spirometry

n=38 in-clinic BDR

n=3 positive,
asthma; n=2
uncertain; n=1

n=34 needed BCT#

Total of n=12
Did not use home spirometry/FeNO
; requiring BCT.
-65% reduction in need for BCT (22/34)

BTS/NICE/SIGN 2024 pathway
Hospital-based

n=7 DNA appointments

n=34 Invited for BCT

n=27 underwent BCT

n=17 negative,
not asthma: n=12
asthma; n=3
uncertain; n=2

n=10 positive,
asthma; n=8
uncertain; n=2

Abbreviations:
FeNO: Fractional exhaled nitric oxide
BDR: Bronchodilator reversibility
BCT: Bronchial challenge testing
FeNOmedian: median FeNO of home measurements
FEV₁%Predmax-min: maximum fluctuation of FEV₁% predicted

#NICE estimated 63% of all suspected asthma will require a BCT following their pathway; BCT is only available in some secondary care services and usually requires onward referral from primary to secondary care.

Symptomatic and GP suspected asthma from primary care

↓

Refer to RADicA clinic

↓

Visit 1:
Clinical history, examination, FeNO, BDR, SPT BEC, ACQ-5 and provide training and device for home diagnosis

→ Two weeks of home testing period

↓

Visit 2:
Device collection, acceptability survey, health-impact questionnaire BCT, inhaler technique.

→ Fluticasone propionate (250mcg twice daily) for 4-8 weeks

↓

Visit 3:
Clinical assessment, physical examination, FeNO, BEC, ACQ-5, BCT

↓

Expert Panel: diagnostic outcomes

Abbreviations:
ACQ-5: 5-item asthma control questionnaire
BDR: Bronchodilator reversibility
BCT: Bronchial challenge testing
FeNO: Fractional exhaled nitric oxide
SPT: Skin prick testing

FeNO variation by patient

Patient_28, Patient_32, Patient_27, Patient_22, Patient_34, Patient_48, Patient_31, Patient_17, Patient_14, Patient_19, Patient_30, Patient_24, Patient_23, Patient_21, Patient_26, Patient_2, Patient_38, Patient_37, Patient_16, Patient_45, Patient_6, Patient_15, Patient_50, Patient_42, Patient_40, Patient_39, Patient_36, Patient_11, Patient_43, Patient_41, Patient_18, Patient_10, Patient_51, Patient_5, Patient_4, Patient_25, Patient_12, Patient_44

Patient ID

FeNO (ppb)

0, 50, 100, 150, 200

Group
- Asthma
- Not asthma
- Uncertain

FEV1 % predicted variation by patient

Patient_21, Patient_25, Patient_32, Patient_18, Patient_41, Patient_15, Patient_35, Patient_43, Patient_31, Patient_44, Patient_28, Patient_38, Patient_40, Patient_27, Patient_23, Patient_34, Patient_39, Patient_51, Patient_24, Patient_48, Patient_30, Patient_29, Patient_22, Patient_47, Patient_9, Patient_12, Patient_50, Patient_17, Patient_16, Patient_19, Patient_37, Patient_14

Patient ID

FEV1 % predicted

40, 60, 80, 100, 120

Group
- Asthma
- Not asthma
- Uncertain